11-04 :: April/May 2011
nanotimes
Companies Facts
um, Gallium, Selenium) solar cells, as measured by the Fraunhofer Institute for Solar Energy (ISE) and the National Renewable Energy Laboratory (NREL). The company also announced an agreement for panel warranty insurance with Munich Re, and member- ship in European panel recycling organization PV Cycle.
http://www.nanosolar.com N
anosphere, Inc. (Nasdaq:NSPH) has initiated commercial launch in Europe. Nanosphere
received CE IVD Mark under the European Directive on In Vitro Diagnostic Medical Devices for its Respi- ratory Virus Plus Nucleic Acid Test, CYP 2C19 Nu- cleic Acid Test for Clopidogrel (Plavix®
) metabolism,
and its Warfarin Metabolism Nucleic Acid Test, all run on the sample-to-result Verigene®
System. The
CE Mark allows commercial distribution in Europe as well as in all countries recognizing the CE Mark. The company has commenced distribution in Italy, Portugal, Spain, Switzerland and Turkey. It expects to begin marketing in most other European markets by year end. Sales and service for Nanosphere‘s Veri- gene System will be provided by distribution partner- ships. About the Tests:
• The Respiratory Virus Plus Test enables rapid detection of respiratory viruses in nearly any hospital setting. This test detects Influenza A, Influenza B, RSV A, and RSV B, as well as Influenza A subtypes, including H1, H3, 2009 H1N1 and the genetic marker H275Y, associated with Oseltamivir (Tamiflu) resistance, on a single cartridge.
• The Clopidogrel Metabolism Test is used to guide the proper anti-platelet drug therapy for patients undergoing percutaneous coronary intervention by
determining whether a patient has genetic varia- tions associated with abnormal metabolism of clopidogrel, commonly known by its brand name, Plavix.
• The Warfarin Metabolism Test is used to detect genetic variations associated with metabolism of warfarin anti-coagulant therapy, known by its most common brand name of Coumadin®
tion may guide therapeutic dosing thereby redu- cing potentially life threatening adverse events.
Furthermore, Nanosphere announced the closing of its previously announced underwritten public offering of 15,686,000 shares of its common stock at a public offering price of $2.20 per share, including 2,046,000 shares of common stock issued pursuant to the underwriters‘ exercise in full of their over-al- lotment option. Piper Jaffray & Co. acted as the sole book-running manager and Roth Capital Partners, LLC acted as co-manager for the offering.
Net proceeds from the sale of the shares after under- writing discounts and commissions and other offering expenses are expected to be approximately $32.1 million. The Company plans to use the net proceeds from the offering for general corporate purposes and working capital.
http://www.nanosphere.us
N
anostart (OTCQX: NASRY)-holding Nanosys, Inc., announced that its next generation LCD
technology, the Quantum Dot Enhancement Film (QDEF™), is available to display manufacturers. Device designers can now increase colour gamut by as much as three times without making the trade offs in cost, size and brightness they’ve had to make
39
. This informa-
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93